These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 34048742)

  • 1. Effects of neurokinin 3 receptor antagonist fezolinetant on hot flash-like symptoms in ovariectomized rats.
    Tahara A; Takamatsu H; Ohtake A; Tanaka-Amino K; Kaku S
    Eur J Pharmacol; 2021 Aug; 905():174207. PubMed ID: 34048742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fezolinetant in the treatment of vasomotor symptoms associated with menopause.
    Depypere H; Lademacher C; Siddiqui E; Fraser GL
    Expert Opin Investig Drugs; 2021 Jul; 30(7):681-694. PubMed ID: 33724119
    [No Abstract]   [Full Text] [Related]  

  • 3. A phase 2b, randomized, placebo-controlled, double-blind, dose-ranging study of the neurokinin 3 receptor antagonist fezolinetant for vasomotor symptoms associated with menopause.
    Fraser GL; Lederman S; Waldbaum A; Kroll R; Santoro N; Lee M; Skillern L; Ramael S
    Menopause; 2020 Apr; 27(4):382-392. PubMed ID: 32102086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of Menopausal Vasomotor Symptoms With Fezolinetant, a Neurokinin 3 Receptor Antagonist: A Phase 2a Trial.
    Depypere H; Timmerman D; Donders G; Sieprath P; Ramael S; Combalbert J; Hoveyda HR; Fraser GL
    J Clin Endocrinol Metab; 2019 Dec; 104(12):5893-5905. PubMed ID: 31415087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of the neurokinin 3 receptor antagonist fezolinetant on patient-reported outcomes in postmenopausal women with vasomotor symptoms: results of a randomized, placebo-controlled, double-blind, dose-ranging study (VESTA).
    Santoro N; Waldbaum A; Lederman S; Kroll R; Fraser GL; Lademacher C; Skillern L; Young J; Ramael S
    Menopause; 2020 Dec; 27(12):1350-1356. PubMed ID: 32769757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized Controlled Trial of Neurokinin 3 Receptor Antagonist Fezolinetant for Treatment of Polycystic Ovary Syndrome.
    Fraser GL; Obermayer-Pietsch B; Laven J; Griesinger G; Pintiaux A; Timmerman D; Fauser BCJM; Lademacher C; Combalbert J; Hoveyda HR; Ramael S
    J Clin Endocrinol Metab; 2021 Aug; 106(9):e3519-e3532. PubMed ID: 34000049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness and safety of fezolinetant in alleviating vasomotor symptoms linked to Menopause.: A systematic review and Meta-Analysis.
    Elnaga AAA; Alsaied MA; Elettreby AM; Ramadan A
    Eur J Obstet Gynecol Reprod Biol; 2024 Jun; 297():142-152. PubMed ID: 38640780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systematic review of neurokinin-3 receptor antagonists for the management of vasomotor symptoms of menopause.
    Cieri-Hutcherson NE; Marji EK; Hutcherson TC
    Menopause; 2024 Apr; 31(4):342-354. PubMed ID: 38471077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurokinin 3 Receptor Antagonism Reveals Roles for Neurokinin B in the Regulation of Gonadotropin Secretion and Hot Flashes in Postmenopausal Women.
    Skorupskaite K; George JT; Veldhuis JD; Millar RP; Anderson RA
    Neuroendocrinology; 2018; 106(2):148-157. PubMed ID: 28380486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fezolinetant: First Approval.
    Lee A
    Drugs; 2023 Aug; 83(12):1137-1141. PubMed ID: 37462862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Novel Nonhormonal Treatment for Vasomotor Symptoms of Menopause.
    Javernick JA
    Nurs Womens Health; 2024 Feb; 28(1):80-84. PubMed ID: 38161058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of fezolinetant for vasomotor symptoms in postmenopausal women: A systematic review and meta-analysis of randomized controlled trials.
    Akhtar SMM; Ali A; Khan MS; Khan V; Fareed A; Saleem SZ; Mumtaz M; Ahsan MN; Iqbal S; Asghar MS
    Int J Gynaecol Obstet; 2024 Sep; 166(3):969-983. PubMed ID: 38563867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neurokinin 3 receptor antagonists for menopausal vasomotor symptoms, an appraisal.
    Gompel A; Stuenkel CA
    Cell Rep Med; 2023 Jun; 4(6):101076. PubMed ID: 37343519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The NK3 Receptor Antagonist ESN364 Suppresses Sex Hormones in Men and Women.
    Fraser GL; Ramael S; Hoveyda HR; Gheyle L; Combalbert J
    J Clin Endocrinol Metab; 2016 Feb; 101(2):417-26. PubMed ID: 26653113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fezolinetant treatment of moderate-to-severe vasomotor symptoms due to menopause: effect of intrinsic and extrinsic factors in two phase 3 studies (SKYLIGHT 1 and 2).
    Santoro N; Nappi RE; Neal-Perry G; English M; King DD; Yamaguchi Y; Ottery FD
    Menopause; 2024 Apr; 31(4):247-257. PubMed ID: 38517210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of fezolinetant, a neurokinin-3 antagonist, in treating vasomotor symptoms in postmenopausal women: A systematic review and meta-analysis.
    Rahman UA; Kashif TB; Usman M; Rana M; Hasanain M; Anjum MU; Cheema HA; Jaffar H; Bhattarai P
    Medicine (Baltimore); 2023 Dec; 102(50):e36592. PubMed ID: 38115258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel ligands balance estrogen receptor β and α agonism for safe and effective suppression of the vasomotor response in the ovariectomized female rat model of menopause.
    McGregor C; Sau A; Ruddy SC; Leung D; Webb M; Durst T; Wright JS; Lagace D; Pratt MA
    Endocrinology; 2014 Jul; 155(7):2480-91. PubMed ID: 24823389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Fezolinetant in Moderate to Severe Vasomotor Symptoms Associated With Menopause: A Phase 3 RCT.
    Johnson KA; Martin N; Nappi RE; Neal-Perry G; Shapiro M; Stute P; Thurston RC; Wolfman W; English M; Franklin C; Lee M; Santoro N
    J Clin Endocrinol Metab; 2023 Jul; 108(8):1981-1997. PubMed ID: 36734148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fezolinetant impact on health-related quality of life for vasomotor symptoms due to the menopause: Pooled data from SKYLIGHT 1 and SKYLIGHT 2 randomised controlled trials.
    Cano A; Nappi RE; Santoro N; Stute P; Blogg M; English ML; Morga A; Scrine L; Siddiqui E; Ottery FD
    BJOG; 2024 Aug; 131(9):1296-1305. PubMed ID: 38320967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term safety of fezolinetant in Chinese women with vasomotor symptoms associated with menopause: the phase 3 open-label MOONLIGHT 3 clinical trial.
    Yu Q; Ming F; Ma J; Cai Y; Wang L; Ren M; Zhang J; Ma X; Miyazaki K; He W; Wang X
    J Int Med Res; 2024 May; 52(5):3000605241246624. PubMed ID: 38818887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.